단국대학교

• 학과소개
• 교수소개
• 교과과정

교수소개

본인은 미국 The Ohio State University에서 약학학사와 PharmD를 취득 후 성균관대학교에서 PhD를 취득하였습니다. 주요 임상경력으로는 미국 Kroger Pharmacy에서의 인턴과 University of Illinois at Chicago 약학대학 및 대학병원에서의 레지던트의 경험이 있습니다. 주요연구분야는 임상약학, 약학교육 및 약물유전체학 입니다. 임상약학 분야에서는 간질환자와 장기이식환자들을 대상으로 한 연구를 진행하였고, 약물유전체학 영역에서는 drug metabolizing enzyme이나 drug transporter의 유전적 다형성에 따른 약물 반응 차이에 대해 연구하였습니다.
현재는 단국대학교 약학대학에서 부교수로 약물치료학, 의약품정보학, 실무실습 등을 담당하고 있습니다.

학력

• [2009] 학사 The Ohio State Univ. / 약학 / 일반약학
• [2011] 석사 The Ohio State Univ. / 약학과 / 임상약학 (Pharm.D.)
• [2015] 박사 성균관대학교(자연과학캠퍼스) / 임상약리학 / 임상약학

주요연구분야

임상약학
심혈관계 약료
약학교육
약물유전체학

연구업적

• 일반논문[20231208] Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict the Pharmacokinetics of Irbesartan in Different CYP2C9 Genotypes
• 일반논문[20230930] 블렌디드 러닝을 활용한 팀 기반 학습 실습 수업에서 약학대학 학생의 학습만족도와 플랫폼 선호도: 예비 연구
• 일반논문[20230801] Effects of CYP2D6 and CYP2C19 genetic polymorphisms and cigarette smoking on the pharmacokinetics of tolperisone
• 일반논문[20230425] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the PK and PD of gliclazide in healthy subjects
• 일반논문[20230301] Systematic Search and Qualitative Evaluation of Dietary Supplement Mobile Applications: Using the Mobile Application Rating Scale (MARS)
• 일반논문[20230201] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects
• 일반논문[20230101] Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone
• 일반논문[20220801] Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes
• 일반논문[20220601] Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes
• 일반논문[20220501] Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism
• 일반논문[20220201] Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects
• 일반논문[20211201] Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes
• 일반논문[20211101] Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients
• 일반논문[20211101] Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin to related CYP2D6*10 allele
• 일반논문[20210801] Korean Women’s Knowledge Level and Social Perception toward Oral Contraceptives and Perspectives on Pharmacy Visits
• 일반논문[20210701] Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism
• 일반논문[20201129] ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan
• 일반논문[20201101] Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide
• 일반논문[20201101] Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes
• 일반논문[20200801] Evaluation of Patient Assessment and Counseling of Over-the-counter Oral Contraceptives by Community Pharmacists in South Korea: A Mystery Shopper Study
• 일반논문[20191201] Effects of steady-state clarithromycin on the pharmacokinetics of zolpidem in healthy subjects
• 일반논문[20191001] Effect of icatibant on angiotensin‐converting enzyme inhibitor‐induced angioedema: A meta‐analysis of randomized controlled trials
• 일반논문[20190101] Evaluation of medication use and pharmacy services for visually impaired persons: Perspectives from both visually impaired and community pharmacists
• 일반논문[20180501] Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes
• 일반논문[20180301] Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites
• 일반논문[20180101] Evaluation of pharmacokinetic, pharmacodynamic, efficacy, and safety data of low-dose ticagrelor versus standard dose in East Asians: a systematic review
• 일반논문[20171201] Inhibition of salivary secretion by tolterodine transdermal patch
• 일반논문[20171101] Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC-MS/MS and its application to a pharmacokinetic study
• 일반논문[20170701] Bioequivalence Study of a New Fixed-dose Combination Tablet Containing S-Amlodipine Nicotinate and Olmesartan Medoxomil in Healthy Korean Male Subjects
• 일반논문[20170301] Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite
• 일반논문[20160801] Characteristics and Career Plans of Korean International Students and Graduates of Doctor of Pharmacy Program in the United States
• 일반논문[20160601] 약학대학 학생들의 교과외활동 현황 평가 및 동기에 대한 분석
• 일반논문[20160601] 근 · 현대사 이후 한국인의 최다 선호 일반의약품의 추이에 대한연대별 분석 및 종합적 의의에 대한 평가
• 일반논문[20151101] Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites.
• 일반논문[20150601] Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects
• 일반논문[20150401] Determination of zolpidem in human plasma by liquid chromatography-tandem mass spectrometry for clinical application.
• 일반논문[20141201] 국내 임상약학 교과과정 현황 및 미국 교과과정과의 비교
• 일반논문[20141101] Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1alpha, did not increase the systemic exposure of pitavastatin.
• 일반논문[20141101] Simultaneous determination of flurbiprofen and its hydroxy metabolite in human plasma by liquid chromatography-tandem mass spectrometry for clinical application
• 일반논문[20141001] Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients
• 일반논문[20140831] 한국 병원의 항생제 치료를 위한 항생제피부반응시험에 대한유효성 및 위험성 평가
• 일반논문[20140801] Response to Suarez-Kurtz's comments on strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals.
• 일반논문[20140430] 한국적 의학 기준에 근거한 고혈압환자의 Angiotensin II Receptor Blockers와 Calcium Channel Blockers의 약물 평가
• 일반논문[20140201] Effects of CYP2C19 Genetic Polymorphisms on Atomoxetine Pharmacokinetics
• 일반논문[20140201] Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals
• 일반논문[20130701] Effects of OCT2 c.602C > T genetic variant on the pharmacokinetics of lamivudine
• 일반논문[20121201] Determination of tolperisone in human plasma by liquid chromatography/tandem mass spectrometry for clinical application
• 일반논문[20120901] Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.
• 일반논문[20120901] Effects of CYP2C9(star)1/(star)3 and (star)1/(star)13 on the pharmacokinetics of losartan and its active metabolite E-3174
• 일반논문[20120601] Evaluating drug therapy decision making in patients with epilepsy
• 일반논문[20120601] Evaluating drug therapy decision making in patients with epilepsy.
• 일반논문[20120501] Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin.
• 일반논문[20120501] Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin
• 일반논문[20111001] Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.
• 일반논문[20111001] Characteristics of 5-hydroxytryptamine receptors involved in contraction of feline ileal longitudinal smooth muscle.

캠퍼스별 교무팀